• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微管相关蛋白 tau(MAPT)促进比卡鲁胺耐药,并与前列腺癌患者的生存相关。

Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.

机构信息

Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

出版信息

Urol Oncol. 2020 Oct;38(10):795.e1-795.e8. doi: 10.1016/j.urolonc.2020.04.032. Epub 2020 May 17.

DOI:10.1016/j.urolonc.2020.04.032
PMID:32430253
Abstract

INTRODUCTION

Microtubule-associated protein tau (MAPT), facilitates tubulin assembly and microtubule stabilization. Several studies have shown that overexpression of MAPT is linked to poor prognosis and is involved in taxane resistance in cancer. This study aimed to assess the expression and function of MAPT in prostate cancer (CaP).

METHODS

The expression of MAPT was determined using immunohistochemistry in CaP. We analyzed the interaction between MAPT, Phosphatase and Tensin Homolog (PTEN), and androgen receptor and investigated the role of MAPT in bicalutamide resistance.

RESULTS

Immunohistochemistry in 155 CaP cases showed that 15% of them were positive for MAPT. High MAPT expression was significantly orrelated with high Gleason score and high T stage. Kaplan-Meier analysis showed that the high MAPT expression was significantly associated with poor prostate-specific antigen recurrence survival after radical prostatectomy. There was an inverse correlation between MAPT and PTEN. In the CaP cell lines, knockout of PTEN increased the expression of MAPT, whereas knockdown of MAPT suppressed the expression of androgen receptor and increased the sensitivity to bicalutamide. Furthermore, immunohistochemical staining of MAPT showed that high MAPT expression was significantly associated with poor overall survival in 74 CaP patients who were treated with androgen deprivation therapy.

CONCLUSION

These results suggest that MAPT may be a promising predictive biomarker for survival and play an essential role in bicalutamide resistance in CaP.

摘要

简介

微管相关蛋白 tau(MAPT)促进微管蛋白组装和微管稳定。多项研究表明,MAPT 的过表达与预后不良有关,并与癌症中的紫杉烷耐药有关。本研究旨在评估 MAPT 在前列腺癌(CaP)中的表达和功能。

方法

使用免疫组织化学方法检测 CaP 中 MAPT 的表达。我们分析了 MAPT 与磷酸酶和张力蛋白同源物(PTEN)和雄激素受体之间的相互作用,并研究了 MAPT 在比卡鲁胺耐药中的作用。

结果

对 155 例 CaP 病例的免疫组化分析显示,其中 15%的病例 MAPT 阳性。高 MAPT 表达与高 Gleason 评分和高 T 分期显著相关。Kaplan-Meier 分析显示,高 MAPT 表达与根治性前列腺切除术后前列腺特异性抗原复发生存不良显著相关。MAPT 与 PTEN 呈负相关。在 CaP 细胞系中,敲除 PTEN 会增加 MAPT 的表达,而敲低 MAPT 会抑制雄激素受体的表达并增加对比卡鲁胺的敏感性。此外,MAPT 的免疫组织化学染色显示,在接受雄激素剥夺治疗的 74 例 CaP 患者中,高 MAPT 表达与总体生存不良显著相关。

结论

这些结果表明,MAPT 可能是一个有前途的预测生存的生物标志物,并在 CaP 中的比卡鲁胺耐药中发挥重要作用。

相似文献

1
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.微管相关蛋白 tau(MAPT)促进比卡鲁胺耐药,并与前列腺癌患者的生存相关。
Urol Oncol. 2020 Oct;38(10):795.e1-795.e8. doi: 10.1016/j.urolonc.2020.04.032. Epub 2020 May 17.
2
Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.微管相关蛋白 tau 的异常表达是前列腺癌的一个独立预后特征。
BMC Cancer. 2019 Mar 1;19(1):193. doi: 10.1186/s12885-019-5390-1.
3
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.PMEPA1基因沉默通过雄激素受体(AR)、NEDD4和磷酸酶及张力蛋白同源物(PTEN)促进前列腺癌细胞生长。
Oncotarget. 2015 Jun 20;6(17):15137-49. doi: 10.18632/oncotarget.3526.
4
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.原钙黏蛋白 B9 促进了对比卡鲁胺的耐药性,并与前列腺癌患者的生存有关。
Prostate. 2019 Feb;79(2):234-242. doi: 10.1002/pros.23728. Epub 2018 Oct 16.
5
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.原发性前列腺癌中核AR-V7蛋白的过表达是接受辅助治疗的高危疾病男性患者的独立不良预后标志物。
Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.
6
Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005.根治性前列腺切除术后高危局限性前列腺癌患者两种辅助激素治疗方案的比较:CU1005研究的主要结果
Asian J Androl. 2016 May-Jun;18(3):452-5. doi: 10.4103/1008-682X.160884.
7
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.抗雄激素阿帕鲁胺(ARN-509)与比卡鲁胺对前列腺癌细胞系雄激素受体通路影响的比较。
Anticancer Drugs. 2018 Apr;29(4):323-333. doi: 10.1097/CAD.0000000000000592.
8
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.Claspin 的过表达促进多西他赛耐药,并与前列腺癌中前列腺特异性抗原的复发相关。
Cancer Med. 2021 Aug;10(16):5574-5588. doi: 10.1002/cam4.4113. Epub 2021 Jul 9.
9
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.辅助放疗、雄激素剥夺治疗及多西他赛用于前列腺癌根治术后高危前列腺癌:NRG肿瘤学/放射肿瘤学组(RTOG)0621研究结果
Cancer. 2017 Jul 1;123(13):2489-2496. doi: 10.1002/cncr.30620. Epub 2017 Mar 21.
10
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.重新定义接受持续雄激素剥夺治疗的前列腺癌患者具有临床意义的去势水平。
J Urol. 2007 Oct;178(4 Pt 1):1290-5. doi: 10.1016/j.juro.2007.05.129. Epub 2007 Aug 14.

引用本文的文献

1
Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease.解析 tau 在性激素反应性癌症中的作用:从阿尔茨海默病中得到的启示。
Clin Sci (Lond). 2024 Nov 6;138(21):1357-1369. doi: 10.1042/CS20230317.
2
Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen.克服比卡鲁胺耐药性的最新进展:透视对新型抗雄激素药物的耐药性
ACS Pharmacol Transl Sci. 2024 Mar 7;7(4):905-914. doi: 10.1021/acsptsci.3c00299. eCollection 2024 Apr 12.
3
Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancer.
微管相关蛋白2(MAP2)在前列腺癌中作为潜在独立预后标志物的表达。
J Cancer Res Clin Oncol. 2024 Feb 4;150(2):76. doi: 10.1007/s00432-023-05579-0.
4
Molecular Targets and Mechanisms of Hedyotis diffusa Willd. for Esophageal Adenocarcinoma Treatment Based on Network Pharmacology and Weighted Gene Co-expression Network Analysis.基于网络药理学和加权基因共表达网络分析的白花蛇舌草治疗食管腺癌的分子靶点及作用机制
Curr Drug Targets. 2024;25(6):431-443. doi: 10.2174/0113894501265851240102101122.
5
Amyloid-beta and tau protein beyond Alzheimer's disease.阿尔茨海默病之外的β淀粉样蛋白和tau蛋白。
Neural Regen Res. 2024 Jun 1;19(6):1262-1276. doi: 10.4103/1673-5374.386406. Epub 2023 Oct 2.
6
Molecular Insight into Prostate Cancer: Preventive Role of Selective Bioactive Molecules.前列腺癌的分子洞察:选择性生物活性分子的预防作用
Life (Basel). 2023 Sep 27;13(10):1976. doi: 10.3390/life13101976.
7
Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.肝癌免疫相关基因的特征分析与临床验证,以辅助预后评估和免疫治疗。
BMC Cancer. 2023 Jun 15;23(1):549. doi: 10.1186/s12885-023-10900-8.
8
Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.鉴定前列腺癌患者比卡鲁胺耐药相关基因及预后预测
Front Endocrinol (Lausanne). 2023 Apr 18;14:1125299. doi: 10.3389/fendo.2023.1125299. eCollection 2023.
9
Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells.有丝分裂时 Tau/MAPT 的磷酸化调节前列腺癌细胞的细胞周期进程。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7689-7701. doi: 10.1007/s00432-023-04721-2. Epub 2023 Mar 31.
10
Tau Isoforms: Gaining Insight into Alternative Splicing.tau蛋白异构体:深入了解可变剪接
Int J Mol Sci. 2022 Dec 6;23(23):15383. doi: 10.3390/ijms232315383.